ColiFin®
Cystic Fibrosis
Marketed (EU)Active
Key Facts
About Spexis
Spexis AG is a publicly traded biopharma focused on discovering and developing novel macrocyclic therapeutics for rare diseases and cancer. Its strategy is built upon two proprietary technology platforms: a Macrocycle Platform for undruggable targets and an OMPTA Platform for antibiotic-resistant Gram-negative infections. The company's most advanced program, ColiFin®, is an approved inhaled therapy for cystic fibrosis, positioning Spexis with a late-stage asset while advancing earlier clinical and pre-clinical candidates. Spexis is actively seeking development and commercialization partners to maximize the value of its pipeline and platforms.
View full company profileTherapeutic Areas
Other Cystic Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-280 | Calithera Biosciences | Preclinical/Phase 1 |
| Ensifentrine | Verona Pharma | Phase 2 |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| Cystic fibrosis (CRISPR) | GeneToBe | Discovery |
| Cystic fibrosis (undisclosed) | GeneToBe | Early Discovery |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| Targeted Lung Delivery | Nanite | Pre-clinical |
| CFTR 100+ Panel | Agena Bioscience | Commercial |
| RIG-301 CFTR | RIGImmune | Pre-clinical |
| CBN-101 | Carbon Biosciences | Preclinical |
| RESP® Biosensor Evaluation (with Rutgers Health) | Strados Labs | Research Study |
| KIT2014 | Kither Biotech | Phase 2 |